u/ClearValue1994

Reddit r/ValueInvesting
· tracked since Jun 2026
Calls 4 1 Posts tracked · 1.0/day Posted today
Calls
7d 4
30d 4
90d 4
Best Calls
COR long +0.6%
Worst Calls
META long -2.6%
BSX long -1.6%
ROP long -0.4%
Most Mentioned
META ×1
ROP ×1
BSX ×1
Recent Calls
ROP long 17 hours ago
META long 17 hours ago
COR long 17 hours ago
Win Rate 25% Long 4 Short 0
Win Rate
7d
30d
90d
Average Return -1.0% Long Return -1.0% Short Return -
Average Return
7d
30d
90d
Result
Result
Sort
Theme Stance
Ticker
Side
Mentions
Opened
Entry
P&L
Thesis
Theme
Source
Long
Jun 10
$49.05
-1.6%
BSX is a Fast Grower with a PEG ratio of 0.59 and trades 24% below the author’s calculated fair value. The Soros “Panic” signal indicates market sentiment is irrationally negative, creating a buying opportunity when fundamentals remain strong. Lynch’s cheap + Soros’ bearish sentiment combination historically precedes mean reversion; BSX offers a margin of safety with growth tailwinds. Medical device regulatory setbacks, slower revenue growth, or a broader healthcare downturn could invalidate the thesis.
BSX is a Fast Grower with a PEG ratio of 0.59 and trades 24% below the author’s calculated fair value. The Soros “Panic” signal indicates market sentiment is irrationally negative, creating a buying opportunity when fundamentals remain strong. Lynch’s cheap + Soros’ bearish sentiment combination historically precedes mean reversion; BSX offers a margin of safety with growth tailwinds. Medical device regulatory setbacks, slower revenue growth, or a broader healthcare downturn could invalidate the thesis.
Healthcare
Long
Jun 10
$279.57
+0.6%
Cencora (COR) is classified as a Fast Grower, PEG 0.64, and 22% below fair value. The combined Lynch/Soros signal suggests the market is overreacting to temporary headwinds, leaving growth priced in at a discount. A classic value/growth crossover – high earnings growth at a low multiple, with sentiment providing extra margin of safety. Drug pricing pressure, supply chain disruptions, or consolidation in pharma distribution.
Cencora (COR) is classified as a Fast Grower, PEG 0.64, and 22% below fair value. The combined Lynch/Soros signal suggests the market is overreacting to temporary headwinds, leaving growth priced in at a discount. A classic value/growth crossover – high earnings growth at a low multiple, with sentiment providing extra margin of safety. Drug pricing pressure, supply chain disruptions, or consolidation in pharma distribution.
Healthcare
Long
Jun 10
$584.50
-2.6%
META is a Fast Grower with PEG 0.91 and trades 14% below estimated fair value. The Soros panic signal indicates excessive bearishness after recent regulatory and spending concerns, but core advertising growth remains robust. While less discounted than other picks, the combination of positive growth momentum and irrational fear provides a reasonable risk/reward. Ad revenue slowdown, heavy capex on AI/metaverse, regulatory crackdowns.
META is a Fast Grower with PEG 0.91 and trades 14% below estimated fair value. The Soros panic signal indicates excessive bearishness after recent regulatory and spending concerns, but core advertising growth remains robust. While less discounted than other picks, the combination of positive growth momentum and irrational fear provides a reasonable risk/reward. Ad revenue slowdown, heavy capex on AI/metaverse, regulatory crackdowns.
AI/Semi
Long
Jun 10
$335.37
-0.4%
Roper Technologies is a Fast Grower, PEG 1.33, yet 20% below fair value per the screen. The PEG above 1.0 is partially offset by the 20% discount and the Soros panic reading, indicating the market is pricing in too much pessimism on its niche software/industrial segments. A buy the dip opportunity in a high‑quality compounder, provided PEG premium is justified by long‑term recurring revenue growth. Integration issues from acquisitions, cyclical exposure, or slower organic growth.
Roper Technologies is a Fast Grower, PEG 1.33, yet 20% below fair value per the screen. The PEG above 1.0 is partially offset by the 20% discount and the Soros panic reading, indicating the market is pricing in too much pessimism on its niche software/industrial segments. A buy the dip opportunity in a high‑quality compounder, provided PEG premium is justified by long‑term recurring revenue growth. Integration issues from acquisitions, cyclical exposure, or slower organic growth.
Other
Showing 4 of 4 picks · sorted by mentions